Comparative effects of three cytokine regimens after high-dose cyclophosphamide: Granulocyte colony-stimulating factor, granulocyte- macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF

Journal of Clinical Oncology

Volumn 17, Issue 4, 1999, Pages 1296-1303

  Ballestrero, Alberto ^a   Ferrando, Fabio ^a   Garuti, Anna ^a   Basta, Palma ^a   Gonella, Roberta ^a   Stura, Paola ^a   Mela, Giuseppe Sandro ^a   Sessarego, Mario ^a   Gobbi, Marco ^a   Patrone, Franco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032962103     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.4.1296     Document Type: Article

References (28)

1. Collins C, Mortimer J, Livingston RB: High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer 63:228-232, 1989
2. Gianni AM, Bonadonna G: High dose chemo-radiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 25:1027-1030, 1989
3. Patrone F, Ballestrero A, Ferrando F, et al: Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 13:840-846, 1995
4. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997
5. Gianni AM, Siena S, Bregni M, et al: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15:2312-2321, 1997
6. Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666-676, 1990
7. Aglietta M, Sanavio F, Stacchini A, et al: Interleukin-3 in vivo: Kinetic of response of target cells. Blood 82:2054-2061, 1993
8. Paquette RL, Zhou JY, Yang YC, et al: Recombinant gibbon interleukin-3 acts synergistically with recombinant human G-CSF and GM-CSF in vitro. Blood 71:1596-1600, 1988
9. Donahue RE, Seehra J, Metzger M, et al: Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241:1820-1823, 1988
10. Geissler K, Valent P, Mayer P, et al: Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates: Synergism with recombinant human granulocyte/ macrophage colony-stimulating factor. Blood 75:2305-2310, 1990
11. Brugger W, Bross K, Frisch J, et al: Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 79:1193-1200, 1992
12. Ganser A, Lindemann, Ottmann OG, et al: Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: Results of a phase I study. Blood 79:2583-2591, 1992
13. Geissler K, Peschel C, Niederwieser, et al: Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells. Br J Haematol 91:299-305, 1995
14. Geissler K, Peschel C, Niederwieser D, et al: Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 87:2732-2739, 1996
15. Rosenfeld CS, Bolwell B, LeFever A, et al: Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Bone Marrow Transplant 17:179-183, 1996
16. Engel H, Korbling M, Palmer J, et al: Randomized trial of G-CSF alone vs sequential interleukin-3 (IL-3) and G-CSF treatment to peripheralize progenitor cells for apheresis and blood stem cell autotransplantation in patients with advanced stage breast cancer. Blood 84:108a, 1994 (abstr 420, suppl 1)
17. 2) cyclophosphamide cancer therapy. Ann Oncol 4:759-766, 1993
18. Bregni M, Siena S, Di Nicola M, et al: Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 14:628-635, 1996
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
20. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400-409, 1991
21. Ballestrero A, Ferrando F, Garuti A, et al: High-dose mitoxantrone with peripheral blood progenitor cell rescue: Toxicity, pharmaco-kinetics and implications for dosage and schedule. Br J Cancer 76:797-804, 1997
22. Hamilton MA, Collings BJ: Determining the appropriate sample size for nonparametric tests for location shift. Technometrics 3:327-337, 1991
23. Hollander G, Wolfe KH: Nonparametric Statistical Methods. New York, NY, John Wiley & Sons, 1974
24. Brugger W, Frisch J, Schulz G, et al: Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 10:1452-1459, 1992
25. Bretti S, Gilleece MH, Kamthan A, et al: An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte macrophage-colony stimulating factor. Eur J Cancer 32A:1171-1178, 1996
26. To LB, Shepperd KM, Haylock DN, et al: Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18:442-447, 1990
27. Ottmann OG, Ganser A, Seipelt G, et al: Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 76:1494-1502, 1990
28. D'Hondt V, Weynants P, Humblet Y, et al: Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 11:2063-2071, 1993